Valneva's Dual Challenge: Legal Scrutiny Meets Commercial Reality

Valneva shares halve after Phase 3 Lyme vaccine trial misses endpoint, triggering a 37% drop and a U.S. law firm investigation. The firm now relies on its chikungunya vaccine for revenue.

The stock of French biotech firm Valneva has been cut in half over the past month, trading at €2.58 on Euronext Paris after a dramatic 46% plunge. This collapse stems from a complex mix of clinical trial data and subsequent legal action, leaving investors to weigh the company's commercial assets against significant uncertainty.

At the heart of the sell-off are the Phase 3 VALOR trial results for the Lyme disease vaccine candidate VLA15, developed with Pfizer. Released on March 23, 2026, the data revealed the vaccine missed its primary endpoint due to an insufficient number of disease cases in the study population, despite showing an efficacy rate over 70% in the primary vaccination schedule. This statistical shortfall triggered an immediate 37% drop in the American Depositary Receipt (ADR) price.

The clinical disappointment was swiftly followed by legal scrutiny. U.S. law firm Pomerantz LLP is investigating whether Valneva and certain executives may have misled investors regarding the trial outcomes. The firm has repeatedly publicized its probe throughout April, maintaining visible legal pressure that continues to weigh on the stock. The share price now sits approximately 50% below its 52-week high of €5.16 and is down about 33% year-to-date.

Financially, the company is navigating this storm with its commercial chikungunya vaccine, IXCHIQ, carrying the load. Valneva reported total revenues of approximately €170 million for 2024. For the current year, management maintains its full-year guidance, projecting total revenues between €155 and €170 million, with €145 to €160 million expected from product sales. The planned shrinkage of third-party distribution business to under 5% of total revenue aims to improve gross margins.

Technically, the chart reflects the severe downturn. The stock is trading roughly 34% below its 50-day moving average of €3.90. A support zone around €2.50 has held so far, just above the 52-week low of €2.37. Analyst firm First Berlin Equity Research reiterated a Buy rating in late March, citing the long-term potential of Valneva's vaccine programs.

Looking ahead, Pfizer remains committed to the Lyme program. Regulatory submissions—a Biologics License Application (BLA) in the U.S. and a Marketing Authorisation Application (MAA) in Europe—are still anticipated, potentially by the end of the year. Significant financial incentives are tied to VLA15's success, including $143 million in near-term milestone payments upon approval, royalties between 14% and 22%, and up to $100 million in additional milestones.

The company's immediate focus turns to its first-quarter 2026 results, scheduled for release on May 7. This report will be a key test for the commercial traction of IXCHIQ, especially following the European approval for adolescents granted in April 2025. Management has been actively engaging investors through conferences in Amsterdam, Boston, and Miami in an effort to maintain institutional support. The Annual General Meeting is set for June 1, 2026.

For now, the path forward hinges on two parallel tracks: the progression of the Pomerantz investigation and the concrete commercial performance of IXCHIQ, which must bridge the gap until VLA15's regulatory fate is decided later this year.